PDF Cover

Sparsentan Tablets Market

The market for Sparsentan Tablets was estimated at $2.4 billion in 2024; it is anticipated to increase to $4.3 billion by 2030, with projections indicating growth to around $7.1 billion by 2035.

Report ID:DS1802084
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Sparsentan Tablets
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Sparsentan Tablets Market Outlook

Revenue, 2024

$2.4B

Forecast, 2034

$6.4B

CAGR, 2025 - 2034

10.5%

The Sparsentan Tablets industry revenue is expected to be around $2.6 billion in 2025 and expected to showcase growth with 10.5% CAGR between 2025 and 2034. The market is positioned for sustained momentum as sparsentan tablets gain strategic importance across nephrology care pathways. Their relevance continues to grow as healthcare systems prioritize targeted treatments for complex kidney disorders, supported by rising diagnostic accuracy, an expanding patient pool, and stronger clinician preference for dual-mechanism therapeutics. Favorable regulatory sentiment for rare-disease interventions and greater investment in specialty pharmaceuticals further enhance market visibility. Additionally, wider inclusion in treatment guidelines and improved reimbursement frameworks across mature markets are accelerating adoption. Collaborations between manufacturers, research institutions and healthcare providers are reinforcing confidence in long-term therapy viability, keeping sparsentan tablets commercially significant and clinically relevant.

Sparsentan tablets, also known as Filspari, are advanced dual endothelin and angiotensin receptor antagonists used primarily for IgA nephropathy and focal segmental glomerulosclerosis. Their ability to combine two mechanisms into one therapy enables more effective proteinuria reduction and long-term kidney protection compared with traditional options. These advantages drive growing utilization across nephrology clinics, especially for patients requiring early intervention or chronic care management. Demand is also supported by rising real-world evidence, increasing payer recognition of their value, and expanding clinical evaluations for additional indications. Recent trends include broader integration into specialty renal-care pathways, strengthened distribution networks and heightened interest in therapies that delay progression toward dialysis. Together, these dynamics establish sparsentan tablets as a critical component of modern renal pharmacotherapy.

Sparsentan Tablets market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Sparsentan Tablets Market Outlook

Market Key Insights

  • The Sparsentan Tablets market is projected to grow from $2.4 billion in 2024 to $6.4 billion in 2034. This represents a CAGR of 10.5%, reflecting rising demand across Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy, and Management of Hypertension.

  • Travere Therapeutics Inc. is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Canada are the top markets within the Sparsentan Tablets market and are expected to observe the growth CAGR of 7.7% to 11.0% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 10.1% to 13.1%.

  • Slow adoption of Shift Toward Dual-Mechanism Therapeutics in Modern Renal Care transition within key players in Sparsentan Tablets market is creating a revenue window for adjacent and alternate markets like Irbesartan Tablets and Candesartan tablets to improve its use-case penetration in and applications and expected to capture $238 million revenue from existing Sparsentan Tablets market.

  • The Sparsentan Tablets market is set to add $4.1 billion between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    rising incidence of kidney disorders, and

    Technological Advancements in Drug Delivery Systems, Sparsentan Tablets market to expand 171% between 2024 and 2034.

sparsentan tablets market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Sparsentan Tablets - Country Share Analysis

Opportunities in the Sparsentan Tablets

A major opportunity for sparsentan tablets emerges from the rapidly growing global IgA nephropathy population, driven by improved diagnostic capabilities and broader clinician awareness. Many regions still rely heavily on monotherapies with limited long-term effectiveness, creating an untapped segment for dual-mechanism options. Sparsentan tablets with strong proteinuria-reducing performance are well positioned to benefit as healthcare systems prioritize early kidney-preservation strategies. Growth is also expected to be strongest in Asia-Pacific and Europe, where IgAN prevalence is high and reimbursement frameworks for innovative renal therapies are progressively expanding.

Growth Opportunities in North America and Europe

North America remains the anchor market for sparsentan tablets, supported by strong clinical adoption in IgA nephropathy and emerging demand in focal segmental glomerulosclerosis. The region benefits from a well-established nephrology ecosystem, rapid payer response frameworks, and high awareness of kidney disease progression risks. Top opportunities include expanded penetration in community nephrology practices, real-world evidence programs enhancing formulary positioning, and broadened uptake as updated KDIGO guidelines and REMS modifications reduce monitoring burdens. Competition intensifies from SGLT2 inhibitors, endothelin receptor antagonists, and pipeline agents such as dual-mechanism kidney therapeutics targeting proteinuria reduction. However, sparsentan retains differentiation through its combined endothelin and angiotensin receptor blockade. Future growth is driven by accelerated approvals, label expansions, and the increasing prevalence of chronic kidney disorders in aging patient cohorts. Strategic collaborations with specialty pharmacies and payers will further strengthen patient access while enabling Travere Therapeutics to defend share in a rapidly evolving therapeutic landscape.
Europe presents a high-value landscape for sparsentan tablets, enabled by the transition from conditional to standard EMA approval and progressively harmonized reimbursement pathways across major markets. The region’s top opportunities include deeper penetration in countries prioritizing early-stage IgAN intervention, expansion through coordinated distribution partnerships with CSL Vifor, and rising demand for therapeutics that delay progression to dialysis. Competition is shaped by entrenched RAAS inhibitors, SGLT2 therapies, and emerging immunomodulatory agents under evaluation for glomerular disorders. Nonetheless, sparsentan’s dual-acting mechanism provides clinical leverage in markets emphasizing proteinuria reduction and long-term renal preservation. Growth is also boosted by improving diagnostic rates, broader inclusion in European nephrology guidelines, and heightened clinician familiarity following multi-country approval cycles. National health systems focused on reducing renal replacement therapy burdens are increasingly favoring disease-modifying therapies, positioning sparsentan as a strategic option. Continued post-marketing surveillance, real-world data generation, and localized education initiatives will reinforce uptake across heterogeneous reimbursement environments.

Market Dynamics and Supply Chain

01

Driver: Growing demand for dual-mechanism renal therapies and rising diagnosis of rare kidney disorders

The sparsentan tablets market is also strongly supported by increasing demand for dual-mechanism renal therapies, which offer enhanced proteinuria reduction and long-term kidney protection compared with conventional monotherapies. This trend is also driven by nephrologists seeking more efficient treatment pathways that combine multiple therapeutic actions in a single tablet, improving adherence and clinical outcomes. Alongside this, the growing diagnosis of rare kidney disorders such as IgA nephropathy and focal segmental glomerulosclerosis is also expanding the eligible patient pool. also advances in biomarker-based screening, wider use of next-generation pathology tools and heightened physician awareness are also allowing earlier detection, enabling targeted treatment adoption. Together, these factors are also reinforcing commercial momentum for sparsentan tablets and positioning dual-acting renal therapies as essential components of modern nephrology care.
A key driver for sparsentan tablets is also the expanding regulatory backing for innovative renal drugs, especially those addressing conditions with significant long-term disease burden. Global health authorities are also accelerating approvals for therapies that demonstrate meaningful improvements in proteinuria reduction and slowing of kidney decline. This trend is also reinforced by rare-disease frameworks, priority review mechanisms and greater emphasis on outcome-based evidence generation. As chronic kidney disease prevalence rises and health systems push for interventions that delay progression toward dialysis, regulators are also increasingly receptive to breakthrough renal therapeutics. Such policy alignment strengthens market confidence, enhances payer willingness to reimburse advanced therapies and accelerates integration of sparsentan tablets across nephrology treatment pathways.
02

Restraint: High treatment cost and limited payer reimbursement hinder broader therapy uptake

One major restraint for sparsentan tablets is the relatively high cost of dual-mechanism therapy coupled with inconsistent reimbursement policies across key markets. In regions with constrained healthcare budgets or restrictive formulary placement, payers may delay coverage or require step therapy through cheaper alternatives before authorizing sparsentan. This limits patient access and suppresses demand, particularly in private insurance and emerging markets, where out-of-pocket expenses deter long-term use. Consequently, revenue growth is tempered as clinicians navigate payer restrictions, often favoring established, lower-cost antihypertensives or proteinuria-reducing drugs that carry narrower clinical benefit but better coverage status.
03

Opportunity: Rising demand for advanced therapies in resistant focal segmental glomerulosclerosis and Growing use in hypertension management among chronic kidney disease patients

Another promising opportunity comes from increasing demand for effective treatments for resistant focal segmental glomerulosclerosis, where therapeutic options remain limited. Sparsentan tablets offer a differentiated dual-receptor blocking mechanism that aligns with unmet needs in high-risk FSGS cases. Providers and specialists are actively seeking therapies that delay progression toward dialysis, creating strong clinical pull. Uptake is expected to rise within specialty nephrology clinics in North America and Western Europe, supported by enhanced real-world evidence, specialist-driven treatment pathways and ongoing clinical research strengthening confidence in long-term disease control.
The growing burden of hypertension associated with chronic kidney disease presents a clear opportunity for sparsentan tablets, particularly among patients requiring tighter, multi-pathway blood pressure regulation. As clinicians shift toward integrated renal–cardiovascular management, sparsentan’s dual-action approach offers significant value over conventional monotherapies. This opportunity is expanding across dialysis-prevention programs and multidisciplinary care centers, where long-term renal protection is prioritized. The strongest growth potential lies in developed markets with mature CKD management frameworks, enabling faster incorporation of advanced therapies that support both vascular stability and kidney-function preservation.
04

Challenge: Competition from established nephrology treatments and other biologic therapies constrains share

Sparsentan tablets face intense competitive pressure from established nephrology treatments such as ACE inhibitors, ARBs, and emerging biologic therapies targeting kidney disease pathways. Clinicians and payers familiar with longstanding regimens may prefer these options due to historical safety data, broader indication profiles, and cost advantages. As a result, sparsentan’s market penetration is slowed in settings where therapeutic inertia favors standard care, limiting overall adoption. This competitive intensity also forces pricing negotiations and can impact pricing strategies, further influencing market dynamics and revenue potential.

Supply Chain Landscape

1

Raw Material Procurement

PfizerMerck & Co
2

API Production

Vertex PharmaceuticalsGlaxoSmithKline
3

Tablet Formulation

AstraZenecaNovartis
4

Distribution & Sale

Walgreens Boots AllianceCVS Health
Sparsentan Tablets - Supply Chain

Use Cases of Sparsentan Tablets in Treatment of Focal Segmental Glomerulosclerosis & Management of Hypertension

Treatment of Focal Segmental Glomerulosclerosis : Sparsentan tablets play an important therapeutic role in managing focal segmental glomerulosclerosis by offering a dual endothelin and angiotensin receptor–blocking effect that helps reduce proteinuria and slow kidney function decline. This type of sparsentan formulation is primarily used in specialized nephrology centers where early intervention is essential to delaying progression toward end-stage renal disease. Clinicians prefer its single-tablet, dual-mechanism approach because it streamlines therapy and provides stronger renal protection compared with conventional monotherapies. Patients with treatment-resistant or high-risk FSGS benefit most, making the medication a valuable option in long-term disease control.
Treatment of IgA Nephropathy : In IgA nephropathy, sparsentan tablets are used to control persistent proteinuria and minimize inflammatory damage within the glomeruli. The dual receptor blockade supports improved renal outcomes, making this type of sparsentan especially useful for adults requiring long-term kidney preservation. Its advantages are most evident in patients who do not achieve sufficient response from standard antihypertensives or immunosuppressive regimens. Nephrologists increasingly recommend sparsentan due to its ability to combine two complementary mechanisms in one therapy, improving adherence and sustained disease control. As diagnostic awareness of IgA nephropathy increases, utilization of sparsentan within specialized renal clinics continues to expand.
Management of Hypertension : Sparsentan tablets are also utilized for managing hypertension in patients with underlying kidney disorders, where blood pressure control is essential for preventing further renal deterioration. Their dual receptor action helps achieve stronger and more consistent blood pressure reduction compared with conventional monotherapy options. This type of sparsentan is often chosen by nephrologists treating complex or resistant hypertension linked to chronic kidney disease. The medication supports long-term vascular and renal protection, making it valuable for patients requiring tighter blood pressure management. Growing clinical preference for integrated renal and cardiovascular risk management continues to support demand in this application.

Recent Developments

Recent developments in sparsentan tablets reflect accelerating momentum in nephrology therapeutics, driven by expanded clinical data, broader regional approvals and growing physician preference for dual-pathway renal treatments. Strategic partnerships and ongoing label-expansion studies are strengthening market positioning, especially in IgA nephropathy and FSGS. A key trend shaping the landscape is the shift toward outcome-based renal care, where therapies demonstrating meaningful proteinuria reduction gain faster adoption. As real-world evidence increases, sparsentan tablets continue to gain credibility as a high-value option within targeted kidney-disease management.

January 2026 : FDA extends review of sparsentan supplemental NDA for FSGS, with a new PDUFA action date of April 13, 2026; Travere prepares for potential commercial launch upon approval, reflecting ongoing regulatory engagement and lifecycle expansion.
September 2025 : CSL Vifor and Travere recognize updated KDIGO clinical practice guidelines recommending FILSPARI for IgA nephropathy patients at risk of progression, reinforcing its positioning in global treatment protocols.

Impact of Industry Transitions on the Sparsentan Tablets Market

As a core segment of the Pharmaceutical industry, the Sparsentan Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Shift Toward Dual-Mechanism Therapeutics in Modern Renal Care and Expansion of Precision Nephrology and Evidence-Driven Treatment Pathways have redefined priorities across the Pharmaceutical sector, influencing how the Sparsentan Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift Toward Dual-Mechanism Therapeutics in Modern Renal Care

A major industry transition supporting sparsentan tablets is the rapid movement toward dual-mechanism renal therapies that simultaneously address multiple pathways driving kidney decline. This transition is reshaping treatment guidelines and encouraging nephrologists to favor single-tablet combination approaches over traditional monotherapies. As a result, pharmaceutical companies are redirecting R&D toward combination receptor antagonists, influencing pipeline strategies across the broader nephrology drug industry. This shift also impacts diagnostic providers, as earlier detection of IgA nephropathy and FSGS becomes essential to match patients with advanced therapies, strengthening integration across the renal-care ecosystem.
02

Expansion of Precision Nephrology and Evidence-Driven Treatment Pathways

Another key transition is the growing emphasis on precision nephrology, where treatment decisions increasingly rely on biomarker insights, risk stratification and real-world evidence. This transition supports wider adoption of sparsentan tablets because their dual-acting design aligns with targeted treatment models. The shift is accelerating collaborations between pharmaceutical manufacturers, specialty clinics and academic research centers to generate outcome-focused data. Downstream impacts include evolving payer frameworks that prioritize therapies delaying dialysis and rising investments in digital patient-monitoring tools, further strengthening the role of advanced renal therapeutics within chronic kidney disease care pathways.